Last week, Teva Pharmaceutical Industries Ltd. (TEVA) announced that an additional administration option for Granix injection has been approved by the FDA. The FDA has approved Granix for self-administration by patients and caregivers.
Teva plans to launch a new Granix syringe for self-administration in early 2015. The currently available Granix syringe is indicated only for administration by a health care professional.
Granix is approved for the reduction in the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
We are pleased with the FDA approving Granix injection for self-administration by patients and caregivers. It will provide a convenient option for patients who have an issue with visiting physicians multiple times.
Other approved neutropenia drugs include Amgen Inc.'s (
AMGN
) Neupogen indicated for the reduction of the risk of infection in patients with tumors, who are receiving strong chemotherapy that may cause severe neutropenia with fever.
Teva plans to launch a new Granix syringe for self-administration in early 2015. The currently available Granix syringe is indicated only for administration by a health care professional.
Granix is approved for the reduction in the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
We are pleased with the FDA approving Granix injection for self-administration by patients and caregivers. It will provide a convenient option for patients who have an issue with visiting physicians multiple times.
Other approved neutropenia drugs include Amgen Inc.'s (
AMGN
) Neupogen indicated for the reduction of the risk of infection in patients with tumors, who are receiving strong chemotherapy that may cause severe neutropenia with fever.
Teva is going to eat some Neupogen for dinner
Aucun commentaire:
Enregistrer un commentaire